GRI Bio Inc
NASDAQ:GRI

Watchlist Manager
GRI Bio Inc Logo
GRI Bio Inc
NASDAQ:GRI
Watchlist
Price: 5.6364 USD 2 772.78% Market Closed
Market Cap: $78.5m

Relative Value

The Relative Value of one GRI stock under the Base Case scenario is hidden USD. Compared to the current market price of 5.6364 USD, GRI Bio Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GRI Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

GRI Competitors Multiples
GRI Bio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
GRI Bio Inc
NASDAQ:GRI
78.5m USD 0 -6 -6.6 -6.6
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR 6.8 -184.5 42.7 196.5
US
Johnson & Johnson
NYSE:JNJ
529.7B USD 5.6 19.8 13.8 16.9
CH
Roche Holding AG
SIX:ROG
275.3B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP 4.9 30.2 19.7 28.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17.2 11.9 13.9
CH
Novartis AG
SIX:NOVN
221.9B CHF 5 19.5 15.7 20.2
US
Merck & Co Inc
NYSE:MRK
269.1B USD 4.2 14.1 10 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
GRI Bio Inc
NASDAQ:GRI
Average P/E: 24.9
Negative Multiple: -6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
Negative Multiple: -184.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
17.2
2%
8.6
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
GRI Bio Inc
NASDAQ:GRI
Average EV/EBITDA: 51.5
Negative Multiple: -6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
42.7
36%
1.2
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
1%
11.9
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
GRI Bio Inc
NASDAQ:GRI
Average EV/EBIT: 121.7
Negative Multiple: -6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
37%
1.1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
196.5
98%
2
US
Johnson & Johnson
NYSE:JNJ
16.9
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.8
23%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
0%
N/A
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5